Oregon Governor John Kitzhaber signed legislation that will transition the state's Medicaid fee-for-service to care coordination
SALEM, ORE.-Last month, Oregon Governor John Kitzhaber signed legislation that will transition the state's Medicaid fee-for-service health plan to one that incentivizes care coordination and primary and preventive care.
Dubbed the "healthcare transformation bill," HB 3650 provides for the creation of coordinated care organizations (CCO)-community-based not-for-profits-comprised of regionalized managed care plans that currently administer the Oregon Health Plan for more than 590,000 low-income residents. At a glance, the program sounds similar to Medicare Accountable Care Organizations (ACOs). The Oregon Health Plan is currently operating under Medicaid waivers.
Under the new design, CCOs would take responsibility for coordinating mental health, physical health and dental care. The state would approve each CCO, and each must create a new delivery model that improves health and lowers costs by emphasizing prevention and improving efficiencies. The CCOs will contract with providers.
"The focus is on transforming the delivery system," Speight says. "That's going to be fascinating to watch because it's hard to do."
While Kitzhaber was determined to craft the CCOs by the end of this legislative session, Erin Fair, senior manager of state and federal regulatory policy for CareOregon, says the legislature "kicked the can" on the issue. Instead, the Oregon Health Authority will convene work groups to focus on CCO criteria; global budget methodology; quality and efficiency metrics; and Medicare-Medicaid integration. Their recommendations will be released in 2012.
"It's too early to tell what it will look like, the details, even who will qualify," Fair says.
CareOregon, a Portland-based non-profit health plan serving Medicaid and Medicare, is now trying to forecast who it will partner with to become a CCO. She says managed care plans can either establish partnerships with outside organizations to develop capacities needed-such as coordinating care with mental health, long-term care management or transitional care services-or bring those services in-house.
"A lot of people are comparing it to speed dating because all the healthcare organizations are having meetings about what they're all doing, as in, 'how do we look to you?'" she says.
Groups will also have to take on the financing, information and marketing roles.
"We're quite interested in the concept of transforming the delivery system through purchasing policy and what can happen between organizing delivery systems and their financing partnerships," Speight says.
More than 80% of Oregon Health Plan clients receive care through managed care organizations. Under the CCO model, a community-based network of providers will care for patients under a global budget with incentives to control costs.
Fair says the model will require health plans to coordinate care. It will require providers to talk to each other and organize services around the member. And it will require navigation assistance to help members move through a complicated system.
Speight speculates that discussions on Medicare ACOs and community care networks will "sharpen the imagination" on how the delivery system at the community level can become more organized and integrated. He sees opportunities for virtual organizations through partnerships and common participation in community-based, not-for-profit organizations.
BUDGET SAVINGS UNCERTAIN
Fair says she is skeptical coordinated care teams will save Oregon the $239 million in the first year of implementation, as projected by advocates of the bill. Oregon, like many other states, is facing a $735 million budget deficit in the next biennium and is looking to existing players in the system to help save money.
A criticism of the bill is that it provides protections to existing managed care organizations, which must meet the criteria of a CCO but do not have to change their business operations until 2017. Because some rural areas will be unable to establish a CCO, the provision allows continued access to current systems for an extended period.
Fair says some think that protection might, in some ways, hinder development because managed care organizations have no incentive to make the kind of changes the state is seeking for several more years.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More